TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03370510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin nasal spray.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pivotal Response Treatment
Description: An evidence-based manualized treatment for individuals with autism, which was specifically designed to improve social communication.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Pivotal Response Treatment
Description: An evidence-based manualized treatment for individuals with autism, which was specifically designed to improve social communication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nasal spray.
Study: NCT02341690

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval walking training
Description: Interval Walking Training with the InterWalk Application An Interval-walking bout will consist of repeated cycles of 3 minutes of fast and 3 minutes of slow walking at 70% and 40% of the smart-phone assessed peak VO2-rate, respectively.~IWT is conducted for at least 60 minutes per day, three days per week. Compliance is monitored continuously using the on-board accelerometer logger
Study: NCT02691494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Estradiol/Norethindrone Acetate
Description: Placebo capsules
Study: NCT04575805

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered Cognitive Bias Modification-Attention (iCBM-A)
Description: The iCBM-A is online CBM intervention for obsessive-compulsive symptoms comprised of delivery of the modified dot-probe task taking place over eight sessions, twice per week for 4 weeks.
Study: NCT02050789

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: flexible duty hours
Description: If a hospital is assigned to the intervention arm, all categorical and preliminary general surgery residents in that general surgery program will switch to the flexible duty hours while at an enrolled hospital.
Study: NCT03951376

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UPRIGHT intervention
Description: The UPRIGHT intervention design consists of two different phases consecutively implemented in two school years: intensive phase and follow-up phase. During the intensive phase, all stakeholders are trained in the UPRIGHT WELL-BEING FOR US programme (18 skills). The follow-up phase (WELL-BEING FOR ALL) intends not only to maintain the effect of the intensive training in youths, but also to boost the positive mental health atmosphere created in the whole school. To do so, different collective activities will be organized at school level such as celebration of thematic days, activities with the community, and outdoor/indoor activities.
Study: NCT04300621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTF 4
Description: Participants will receive (S)-ketamine administered sublingually through OTF 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTF 4
Description: Participants will receive (S)-ketamine administered sublingually through OTF 4.
Study: NCT02341690

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: Standard care at the promotion centre in the municipality
Study: NCT00646984

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard continuous antiretroviral therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD-4 guided therapy interruption
Description: Stop antiretroviral therapy when CD-4 equal or above 350 and reinitiate when below 350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viral load driven treatment interruption
Description: Stop antiretroviral therapy when viral load below 30,000 copies/ml and reinitiate when equal or above 30,000 copies/ml
Study: NCT03515044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg Rifaximin SSD once daily
Description: SSD once daily (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg Rifaximin SSD twice daily
Description: SSD twice daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80 mg Rifaximin SSD once daily
Description: SSD once daily (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80 mg Rifaximin SSD twice daily
Description: SSD twice daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered twice daily (BID)
Study: NCT03332433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula oxygenation
Description: Oxygen is supplied with a high-flow nasal cannula oxygenation device，the flow is up to 60L/min
Study: NCT04348422

Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 RT-PCR
Description: Nasoropharyngeal swabs for COVID-19 RT-PCR - initial screening/retest +every 10 days in 100 days followup period

Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 RT-PCR
Description: Nasoropharyngeal swabs for COVID-19 RT-PCR - initial screening/retest +every 10 days in 100 days followup period

Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 Serology
Description: Blood samples for COVID-19 serology - initial screening/retest +every 10 days in 100 days followup period Each sample will be examined by 4-6 serology kits.

Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 Serology
Description: Blood samples for COVID-19 serology - initial screening/retest +every 10 days in 100 days followup period Each sample will be examined by 4-6 serology kits.

Intervention type: OTHER
Intervention: Symptoms questionnare
Description: Symptoms questionnaire which will be filled by participant on initial screening/retest visit + every 10 days in 100 days followup period

Intervention type: OTHER
Intervention: Symptoms questionnare
Description: Symptoms questionnaire which will be filled by participant on initial screening/retest visit + every 10 days in 100 days followup period
Study: NCT01624233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80 mg ixekizumab
Description: Administered SC
Study: NCT02364258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin 10mg tablet (ages 8-21 years); 1 time dose given per oral at the start of the study day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 10mg tablet (ages 8-21 years); 1 time dose given per oral at the start of the study day.
Study: NCT03573336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: Intake orally, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: Intake orally, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Intake orally, once daily
Study: NCT04148287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX001
Description: Day 1: APX001 1000 mg IV BID over a 3-hour infusion Days 2-3: APX001 600 mg IV QD over a 3-hour infusion Days 4 - 42: APX001 600 mg IV QD over a 3-hour infusion or APX001 800 mg QD oral.
Study: NCT03382041

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbon Fiber Implant
Description: A cannulated rod, made of long carbon fiber reinforced polymer, with interlocking holes at its proximal and distal ends. The Nail provides for a slight bend. A Tantalum radiopaque marker along the Nail longitudinal axis provides for its visualization under fluoroscopy. The Nail proximal end is marked by a tantalum marker.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Titanium Implant
Description: An intramedullary rod, also known as an intramedullary nail (IM nail) or inter-locking nail or Küntscher nail (without proximal or distal fixation), is a metal rod forced into the medullary cavity of a bone. IM nails have long been used to treat fractures of long bones of the body
Study: NCT02691676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasmalyte
Description: Parenteral administration of Plasmalyte initiated immediately after collection of the first blood sample at 166 mL/hour. Thus, all patients received 1000 mL of infusion solution over 6 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringerfundin
Description: Parenteral administration of Ringerfundin initiated immediately after collection of the first blood sample at 166 mL/hour. Thus, all patients received 1000 mL of infusion solution over 6 hours.
Study: NCT03590119

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lutetium Lu 177-DOTATATE
Description: Intra-arterial infusion of Lu-177-DOTATATE

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium Lu 177-DOTATATE
Description: Intra-arterial infusion of Lu-177-DOTATATE
Study: NCT03113227

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Transvaginal ultrasound
Description: Transvaginal ultrasound will be made for assessment of posterior cervical angle and cervical length

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Transvaginal ultrasound
Description: Transvaginal ultrasound will be made for assessment of posterior cervical angle and cervical length

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal examination
Description: Vaginal examination will be done for assessment of Bishop score

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal examination
Description: Vaginal examination will be done for assessment of Bishop score
Study: NCT00154258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Study: NCT01887795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WBRT
Study: NCT00494013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro Protamine Suspension
Description: Patient specific dose administered subcutaneously once daily or twice daily x 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Detemir
Description: Patient specific dose administered subcutaneously once or twice daily x 24 weeks.
Study: NCT00882219

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xience V®
Description: Placement of a Xience V® stent within a restenosed bare metal stent.
Study: NCT00737464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: iv (120, 200 or 360 micrograms) every 4 weeks for 12 weeks.
Study: NCT02827565

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KRAS, NRAS et BRAF mutation analysis from circulating plasma DNA
Description: 10 ml blood sample
Study: NCT03703570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-6356
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-6356
Description: Oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration
Study: NCT03867916

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation Program
Description: Use patient navigation program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT02484716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol nasal spray
Description: Timolol 0.5% is administered by the patient with a posology of one spray (50 µL) in each nostril twice a day for 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: Placebo (NaCl) is administered by the patient with a posology of one spray (50 µL) in each nostril twice a day for 4 weeks.
Study: NCT03212651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg IV infusion
Study: NCT03807193

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-selected treatment
Description: The participants will select their own treatment material with the help of a written manual. The interventions possible to choose are all interventions used in standard cognitive behavior therapy for anxiety and depression.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-selected treatment
Description: The participants will select their own treatment material with the help of a written manual. The interventions possible to choose are all interventions used in standard cognitive behavior therapy for anxiety and depression.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Predetermined treatment
Description: The participants will be given a treatment program designed to address worry and generalized anxiety disorder. The program are based on newer forms of cognitive behavior therapy and include mindfulness and acceptance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Predetermined treatment
Description: The participants will be given a treatment program designed to address worry and generalized anxiety disorder. The program are based on newer forms of cognitive behavior therapy and include mindfulness and acceptance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly support
Description: The participants will have scheduled weekly support, once a week, during the treatment. The support till be delivered by students in clinical psychology.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly support
Description: The participants will have scheduled weekly support, once a week, during the treatment. The support till be delivered by students in clinical psychology.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support on demand
Description: The participants will have support if and when they ask for it by themselves. If asked for the support will be delivered by students in clinical psychology.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support on demand
Description: The participants will have support if and when they ask for it by themselves. If asked for the support will be delivered by students in clinical psychology.
Study: NCT02303340

Intervention type: RADIATION
Intervention: Dual Energy X-ray Absorptiometry
Study: NCT02691494

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Estradiol/Norethindrone Acetate
Description: Placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol/Norethindrone Acetate
Description: Commercially-available E2/NETA tablets were over-encapsulated to maintain study blinding.
Study: NCT02856919

Intervention type: DRUG
Group type: OTHER
Intervention: brimonidine tartrate
Description: Mirvaso® gel (5 mg/g brimonidine tartrate)
Study: NCT02691494

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Elagolix
Description: Film-coated placebo tablets
Study: NCT02142829

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EXPAREL
Study: NCT01749085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04449913, ketoconazole
Description: Subjects receive a 200 mg oral dose of PF-04449913 under fasted conditions with washout, then single 200 mg oral dose of PF-04449913 under fed with washout and finally a single 200 mg dose 0f PF-04449913 following dosing to steady state with ketoconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04449913, ketoconazole
Description: Subjects receive a 200 mg oral dose of PF-04449913 under fed conditions with washout, then single 200 mg oral dose of PF-04449913 under fasted with washout and finally a single 200 mg dose of PF-04449913 following dosing to steady state with ketoconazole
Study: NCT02142829

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: On-Q Pain Ball
Description: bupivacaine HCl 0.25%
Study: NCT03357497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very early mobilization
Description: The patient will be mobilized by a physiotherapist in our postoperative care unit. The intervention uses the SOMS protocol.
Study: NCT03086876

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Level 4 Stepping Stones Triple P (SSTP)
Description: Stepping Stones Triple P is a system of psychoeducational and behavioural approaches to parenting a child with LD and challenging behaviour that aims to increase parental confidence and skills so that parents are able to manage the child's behavior effectively. SSTP comprises different levels based on increasing family complexity.
Study: NCT02189629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD5789 (trifarotene)
Study: NCT02446288

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMJ Next Generation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DSG Relaxer
Study: NCT02333162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMTMI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Marrow Irradiation
Description: Undergo IMTMI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic PBSCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic PBSCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: Undergo allogeneic BMT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV or PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04136288

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MoreNova
Description: Shockwave therapy delivered to the genital area with low dose shocks
Study: NCT06238856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLIT™ Amikacin
Description: Amikacin administered via the Pari LC STAR™ nebulizer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLIT™ Amikacin
Description: Amikacin administered via the Pari LC STAR™ nebulizer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLIT™ Amikacin
Description: Amikacin administered via the Pari LC STAR™ nebulizer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Nebulized saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Nebulized saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Nebulized saline.
Study: NCT01612364

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracic sympathetic block
Description: Thoracic sympathetic block is sympathetic block of upper limb described by Leriche e Fontaine em 1925. The block is performed under radioscopic view, positioning the needle lateral the body of thoracic vertebra T3, where infuse anesthetic solution. The theoretical advantage over the stellate ganglion is its greater specificity and efficiency. Solution block: 5ml ropivacaine 0,75% + 5ml de triamcinolone 2%

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thoracic sympathetic block
Description: Thoracic sympathetic block is sympathetic block of upper limb described by Leriche e Fontaine em 1925. The block is performed under radioscopic view, positioning the needle lateral the body of thoracic vertebra T3, where infuse anesthetic solution. The theoretical advantage over the stellate ganglion is its greater specificity and efficiency. Solution block: 5ml ropivacaine 0,75% + 5ml de triamcinolone 2%
Study: NCT02842242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MYK-461
Study: NCT02539758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ocular massage
Description: ocular massage could be applied over the globe over the closed eyelids with moderate massage strength for 15 minutes. The compression of the globe was given with finger, and press for 2 seconds, then by a 2 seconds release, with a frequency of 15 presses/minute.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LenstarLS900
Description: observed changes of anterior chamber depth before and after ocular massage by LenstarLS900

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Goldmann tonometer
Description: observed changes of intraocular pressure before and after ocular massage by Goldmann tonometer
Study: NCT03792984

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 (Cholecalciferol) (6000 IU/daily). PO for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate
Description: Calcium carbonate (1000 mg/daily). PO for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin (1500 mg/daily; the metformin dose was increased stepwise, starting with 500 mg once daily for the 1st week, 500 mg twice daily in the 2nd week, followed by 500 mg 3 times daily from the 3rd week onward). PO for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin (1500 mg/daily; the metformin dose was increased stepwise, starting with 500 mg once daily for the 1st week, 500 mg twice daily in the 2nd week, followed by 500 mg 3 times daily from the 3rd week onward). PO for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PO for 8 weeks.
Study: NCT01337687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin
Description: Oxytocin administered intranasally twice a day via 1 12 unit puff to each nostril, totaling 48 IU a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline will be administered intranasally twice a day via 1 puff per nostril, totaling 48 IU a day.
Study: NCT00998764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bapineuzumab 0.5 mg/kg
Description: I.V., 0.5 mg/kg, infusion every 13 weeks for a total of 16 infusions.
Study: NCT00057681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Description: Titrated until blood level is 1.1 to 1.3 mEq/L

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproate
Description: Titrated until blood level is 111 to 125 ug/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Titrated by weight until dose is 2.0 mg BID to 3.0 mg BID
Study: NCT00625482

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: OPV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OPV plus BCG